Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Cheung
    Cheung
  8. Voss
    Voss
  9. O'Reilly
    O'Reilly
  10. Robson
    Robson

Groups

  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)
  7. Epidemiology and Biostatistics (151)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (121)
  10. Surgery (118)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (556)
  2. Solid Tumor Oncology Division (454)
  3. GSK Faculty (290)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (158)
  6. Hematologic Malignancies, Division of (152)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Roberta Zappasodi (24)

More People

Years
  1. 2025 (28)
  2. 2024 (63)
  3. 2023 (45)
  4. 2022 (123)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (404)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (46)
  5. Journal of Hematology & Oncology (42)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Case studies of sarcoma and MRCLS following treatment with NY-ESO-1 TCR T Cells (GSK3377794): Correlates of predictable response characteristics
    Meeting Abstract

    Van Tine, B.; D'Angelo, S.; Gyurdieva, A.; Johnson, L.; Turner, D.; Tress, J.; DeYoung, M. P.; Wu, Y.; Hasan, A.; Araujo, D.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A.; Olszanski, A.; Hornyak, T.; Wolchok, J.; Vetrhus, S.; Handeland, K. R.; Kuryk, L.; Jaderberg, M.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma
    Meeting Abstract

    Shoushtari, A.; Middleton, M.; Stevens, N.; Evans, T.; Infante, J.; Sznol, M.; Anthoney, A.; Gupta, A.; Woodcock, V.; Wiseman, T.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Defining the TCR repertoire and functional differentiation of tumor-infiltrating T cells in mice responding to radiotherapy and CTLA-4 blockade
    Meeting Abstract

    Rudqvist, N. P.; Lhullier, C.; Wennerberg, E.; Sims, J.; Demaria, S.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer
    Meeting Abstract

    Sen, T.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers
    Meeting Abstract

    Ott, P.; Govindan, R.; Naing, A.; Friedlander, T.; Margolin, K.; Lin, J.; Bhardwaj, N.; Hellmann, M.; Awad, M.; Wanamaker, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; O'Hara, M.; Bhardwaj, N.; Gordon, M.; Hauke, R.; Bordoni, R.; Khalil, D.; Rawls, T.; Vitale, L.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
    Meeting Abstract

    Nissola, L.; Autio, K.; Bhardwaj, N.; Galsky, M.; Wentzel, K.; Lucey, V.; Selinsky, C.; Perry, C.; Cabanski, C.; Bitton, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Krieger, P.; Sanchez-Vega, F.; Schultz, N.; Shoushtari, A.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
    Meeting Abstract

    Ma, J.; Klatt, M.; Dundar, F.; Zumbo, P.; Femia, M.; Betel, D.; Scheinberg, D.; Baker, B.; Klebanoff, C.; Chandran, S.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save